Plus: The ongoing financial struggles of rural hospitals, a major measles outbreak and the FDA approves treatment for a rare ...
Novartis acquires Anthos' abelacimab for $925M upfront and up to $3.1B total, marking CEO Bill Meury's second major exit and ...
The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...
Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback